A discrete choice experiment to understand preferences of patients with type 2 diabetes about the attributes of GLP1 receptor agonists in Spain

Objective: To determine the preferences regarding injection, medication frequency and complexity of GLP1 receptor agonists among patients with type 2 diabetes, treatment-na & iuml;ve for such drugs in Spain. Additionally, patients' willingness to pay according to these attributes was evaluated. Methods: A discrete-choice experiment survey designed to evaluate patients' preferences over three attributes discriminating by age, sex and patients experience with previous injectable treatment was fulfilled by patients. The resulting model was analyzed using a conditional (fixed-effects) logistic regression. Results: A total of 180 patients (63.35 +/- 11.49 years, 63.28% men, 48.41% with previous cardiovascular disease, 54.69% with a time of evolution of diabetes >10 years) recruited from 5 health care centers in Spain completed the survey. Patients viewed positively weekly injections (vs daily injections), but rated negatively a complex preparation of the dose (vs simple preparation). Whereas na & iuml;ve patients for injectable medications did not consider administration timing of importance, no na & iuml;ve patients considered it relevant. No relevant differences were observed according to age or gender. Patients were willing to pay 83.25<euro>for a "no preparation required" dose. No na & iuml;ve and na & iuml;ve patients were willing to pay 34.61<euro> and 14.35<euro>; p = 0.000, to change daily injection for a weekly injection. Conclusions: Patients highly valued the avoidance of injections, with weekly dosing clearly preferred over daily dosing, as well as reducing the treatment complexity. These findings may provide a better understanding of what patients prefer and value in their treatment and provide guidance for clinicians making therapeutic decisions regarding treatments of patients with type 2 diabetes.